Noticias

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Financial Times

Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector

Leer el informe completo de Veytics

Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.